Article Information
History
- August 1, 2021.
Article Versions
- Version 1 (July 22, 2021 - 08:14).
- You are currently viewing Version 2 of this article (August 1, 2021 - 23:12).
- Version 3 (September 16, 2021 - 11:31).
- View Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- James M. Musser, MD, PhD1,*,
- Paul A. Christensen, MD1,
- Randall J. Olsen, MD, PhD1,
- S. Wesley Long, MD, PhD1,
- Sishir Subedi, MS1,
- James J. Davis, PhD2,
- Parsa Hodjat, MD1,
- Debbie R. Walley, MD1,
- Jacob C. Kinskey, MD1 and
- Jimmy Gollihar, PhD3
- 1Center for Infectious Diseases, Houston Methodist Research Institute and Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas
- 2Computing, Environment and Life Sciences, Argonne National Laboratory, Lemont, Illinois
- 3CCDC Army Research Laboratory-South, Austin, Texas
- ↵*Corresponding Author:
James M. Musser, MD, PhD, Department of Pathology and Genomic Medicine, Houston Methodist Hospital and Houston Methodist Research Institute, Houston, TX 77030 (jmmusser{at}houstonmethodist.org).
Posted August 01, 2021.
Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas
